Coly-Mycin M Parenteral
Coly-Mycin M Parenteral Uses, Dosage, Side Effects, Food Interaction and all others data.
Each vial contains Coly-Mycin M Parenteral Sodium 1 MIU or 34 mg Colistin.Each vial contains Coly-Mycin M Parenteral Sodium 2 MIU or 68 mg Colistin.Each vial contains Coly-Mycin M Parenteral Sodium 3 MIU or 102 mg Colistin.Each vial contains Coly-Mycin M Parenteral Sodium 4.5 MIU or 150 mg Colistin.Coly-Mycin M Parenteral sodium is a surface active agent which penetrates into and disrupts the bacterial cell membrane. It has been shown to have bactericidal activity against Aerobic gram-negative microorganisms e.g. Enterobacter aerogenes, E. coli, Klebsiella pneumoniae and PseudomonasColy-Mycin M Parenteral is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Coly-Mycin M Parenteral is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.
Coly-Mycin M Parenteral is a polymyxin antibiotic agent. Originally, colistimethate sodium was thought to be less toxic than polymyxin B; however, if the drugs are administered at comparable doses, their toxicities may be similar. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins.
Trade Name | Coly-Mycin M Parenteral |
Availability | Prescription only |
Generic | Colistimethate |
Colistimethate Other Names | Colistin methanesulfonic acid, Colistin sulfomethate, Colistinmethanesulfonic acid |
Related Drugs | penicillin g potassium, Pfizerpen, Coly Mycin M |
Type | Injection |
Formula | C58H105N16O28S5 |
Weight | Average: 1634.87 Monoisotopic: 1633.588775306 |
Groups | Approved, Vet approved |
Therapeutic Class | Other antibacterial preparation |
Manufacturer | |
Available Country | United States |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Coly-Mycin M Parenteral is used for the treatment of acute or chronic infections caused by sensitive strains of certain gram-negative bacilli. It is particularly used for the infection caused by sensitive strains of Pseudomonas aeruginosa. Coly-Mycin M Parenteral is not used for infections due to Proteus or Neisseria. Coly-Mycin M Parenteral is very effective in the treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
Coly-Mycin M Parenteral is also used to associated treatment for these conditions: Bacterial Infections
How Coly-Mycin M Parenteral works
Coly-Mycin M Parenteral is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Coly-Mycin M Parenteral is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.
Dosage
Coly-Mycin M Parenteral dosage
Maintenance dose: 9 MIU/day in 2-3 divided doses. In patients who are critically ill, a loading dose of 9 MIU should be administered.
Renal impairment patients: Dose adjustments in renal impairment patients are necessary. Dose reductions are recommended for patients with creatinine clearance < 50 ml/min. Twice daily dosing is recommended.
- Creatinine clearance <50-30 ml/min: daily dose 5.5-7.5 MIU
- Creatinine clearance <30-10 ml/min: daily dose 4.5-5.5 MIU
- Creatinine clearance <10 ml/min: daily dose 3.5 MIU
- No-HD days: 2.25 MIU/day (2.2-2.3 MIU/day).
- HD days: 3 MIU/day (Should be given after the HD session) Twice daily dosing is recommended.
- Children ≤40 kg: 75,000-150,000 IU/kg/day divided into 3 doses.
- Children >40 kg: >150,000 IU/kg/day has been reported in children with cystic fibrosis.
Direct Intermittent Administration- Slowly inject one-half of the total daily dose over a period of 3 to 5 minutes every 12 hours.
Continuous Infusion- Slowly inject one-half of the total daily dose over 3 to 5 minutes. Add the remaining half of the total daily dose of Coly-Mycin M Parenteral for injection to one of the following:
- 0.9% NaCl
- 5% dextrose in 0.9% NaCl
- 5% dextrose in water
- 5% dextrose in 0.45% NaCl
- 5% dextrose in 0.225% NaCl
- Lactated Ringer's solution
Alternative method- As per specialized references for intermittent infusion: Prescribed dose can be diluted in 50-100 ml 0.9% NaCl and administer over 30-60 minutes in IV route.
Side Effects
The following adverse reactions have been reported: gastrointestinal upset, tingling of extremities and tongue, slurred speech, dizziness, vertigo and paresthesia, generalized itching, urticaria and rash, fever, increased blood urea nitrogen (BUN), elevated creatinine and decreased creatinine clearance, respiratory distress and apnea, nephrotoxicity and decreased urine output.
Toxicity
Oral LD50 in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.
Precaution
Coly-Mycin M Parenteral should be used with caution in patient with impaired renal function. When actual renal impairment is present, Coly-Mycin M Parenteral may be used, but the greatest caution should be exercised and the dosage should be reduced in proportion to the extent of the impairment. Coly-Mycin M Parenteral should be used with caution in neonates, infants and children.
Interaction
Coly-Mycin M Parenteral should not be given with certain antibiotics like- aminoglycosides and polymyxin due to report of interfere with the nerve transmission at the neuromuscular junction. It should not be given with muscle relaxants e.g., tubocurarine and other drugs including ether, succinylcholine, gallamine, decamethonium and sodium citrate. The concomitant use of Sodium Cephalothin and Coly-Mycin M Parenteral should be avoided.
Food Interaction
No interactions found.Coly-Mycin M Parenteral Drug Interaction
Moderate: sulfamethoxazole / trimethoprim, sulfamethoxazole / trimethoprimUnknown: pancrelipase, pancrelipase, heparin, heparin, acetaminophen, acetaminophen, budesonide, budesonide, dornase alfa, dornase alfa, montelukast, montelukast, valproic acid, valproic acid, ascorbic acid, ascorbic acid, cholecalciferol, cholecalciferol
Coly-Mycin M Parenteral Disease Interaction
Elimination Route
Very poor absorption from gastrointestinal tract.
Half Life
2-3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.
Pregnancy & Breastfeeding use
There are no adequate and well-controlled studies about the use of Coly-Mycin M Parenteral in pregnant women. Since colistimethate is transferred across the placental barrier in humans, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Coly-Mycin M Parenteral is excreted in human breast milk. Therefore, caution should be exercised when administered to nursing women.
Contraindication
The use of Coly-Mycin M Parenteral Sodium Parenteral is contraindicated for patients with a history of sensitivity to the drug or any of its components.
Acute Overdose
Overdosage with colistimethate sodium can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death. Overdosage with the drug can also cause acute renal failure, manifested as decreased urine output and increases in serum concentrations of B.U.N and creatinine. As in any case of overdose, Coly-Mycin M Parenteral Sodium therapy should be discontinued and general supportive measures should be utilized.
Storage Condition
Before reconstitution: Store below 30°C. After reconstitution: Store at 2°C to 8°C (Do not freeze) and use within 24 hours.
Innovators Monograph
You find simplified version here Coly-Mycin M Parenteral
Coly-Mycin M Parenteral contains Colistimethate see full prescribing information from innovator Coly-Mycin M Parenteral Monograph, Coly-Mycin M Parenteral MSDS, Coly-Mycin M Parenteral FDA label